Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     
  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     
  • Bitcoin GBP

    51,663.79
    -1,208.04 (-2.28%)
     
  • CMC Crypto 200

    1,371.97
    +59.35 (+4.52%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • DOW

    37,986.40
    +211.02 (+0.56%)
     
  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

Shire plc : Director/PDMR Shareholding

Director/PDMR Shareholding October 5, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") Notification of transactions by person discharging managerial responsibilities

1.

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated them ("PCA")

a)

Name

Bill Mordan

2.

Reason for the notification

a)

Position / status

General Counsel and Company Secretary - PDMR

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor

a)

Name

Shire plc

b)

LEI

54930005LQRLI2UXRQ59

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Shire plc American Depositary Shares ("ADSs")



Identification code

ISIN: US82481R1068

b)

Nature of the transaction

Receipt of ADSs following the vesting of Restricted Stock Units ("RSUs") awarded under the Shire Long Term Incentive Plan 2015 ("LTIP") on February 12, 2016. The date of vesting follows the second anniversary of the originally intended date of grant of October 1, 2015. In accordance with the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the RSUs from the award date to the date of vesting.



(Details of related disposal of ADSs are referenced in section 5. below.)

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$0

5,208

d)

Aggregated information

- Aggregated volume

- Price

N/A (single transaction)

e)

Date of the transaction

October 3, 2017

f)

Place of the transaction

N/A

5.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Shire plc American Depositary Shares ("ADSs")



Identification code

ISIN: US82481R1068

b)

Nature of the transaction

Automated disposal of ADSs in relation to the vesting of RSUs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$153.2803

1,748

d)

Aggregated information

- Aggregated volume

- Price

N/A (single transaction)

e)

Date of the transaction

October 3, 2017

f)

Place of the transaction

NASDAQ

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations

Ian Karp

ikarp@shire.com

+1 781 482 9018

Robert Coates

rcoates@shire.com

+44 1256 894874

Media

Lisa Adler

lisa.adler@shire.com

+1 617 588 8607

Katie Joyce

kjoyce@shire.com

+1 781 482 2779

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

ADVERTISEMENT

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Shire plc via GlobeNewswire

HUG#2139714